Intellia Therapeutics Inc [NTLA] stock is trading at $32.39, down -0.83%. An important factor to consider is whether the stock is rising or falling in short-term value. The NTLA shares have gain 17.10% over the last week, with a monthly amount glided 28.23%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 22, February 2024, Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress. In a post published today on Yahoo Finance, On track to dose the first patient in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy in Q1 2024.
From an analyst’s perspective:
Intellia Therapeutics Inc [NASDAQ: NTLA] stock has seen the most recent analyst activity on February 23, 2024, when Goldman downgraded its rating to a Neutral and also revised its price target to $32 from $136. On April 13, 2023, Canaccord Genuity initiated with a Buy rating and assigned a price target of $66 on the stock. Bernstein started tracking the stock assigning a Outperform rating and suggested a price target of $54 on March 21, 2023. BMO Capital Markets upgraded its rating to a Outperform and raised its price target to $57 on March 14, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on February 01, 2023, and assigned it a price target of $67. In a note dated January 24, 2023, Citigroup upgraded an Neutral rating on this stock and revised its target price from $48 to $39.
Intellia Therapeutics Inc [NTLA] stock has fluctuated between $22.67 and $47.48 over the past year. Currently, Wall Street analysts expect the stock to reach $131.76 within the next 12 months. Intellia Therapeutics Inc [NASDAQ: NTLA] shares were valued at $32.39 at the most recent close of the market. An investor can expect a potential return of 306.79% based on the average NTLA price forecast.
Analyzing the NTLA fundamentals
Intellia Therapeutics Inc [NASDAQ:NTLA] reported sales of 36.27M for the trailing twelve months, which represents a drop of -114.12%. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -14.21%, Pretax Profit Margin comes in at -13.27%, and Net Profit Margin reading is -12.97%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.43 and Total Capital is -0.43. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 31.63 points at the first support level, and at 30.88 for the second support level. However, for the 1st resistance point, the stock is sitting at 33.21, and for the 2nd resistance point, it is at 34.04.
Intellia Therapeutics Inc [NTLA] reported earnings per share of -$1.46 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.45/share, meaning a difference of -$0.01 and a surprise factor of -0.70%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.38 per share as compared to estimates of -$1.5 per share, a difference of $0.12 representing a surprise of 8.00%.
Ratios To Look Out For
For context, Intellia Therapeutics Inc’s Current Ratio is 8.67. On the other hand, the Quick Ratio is 8.67, and the Cash Ratio is 1.97. Considering the valuation of this stock, the price to sales ratio is 85.83, the price to book ratio is 2.87.
Transactions by insiders
Recent insider trading involved Sepp-Lorenzino Laura, EVP, Chief Scientific Officer, that happened on Jan 08 when 2275.0 shares were sold. President and CEO, LEONARD JOHN M completed a deal on Jan 03 to sell 19223.0 shares. Meanwhile, EVP, Chief Medical Officer Lebwohl David sold 5843.0 shares on Jan 03.
